Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evgen Pharma ( (GB:TCF) ) has provided an update.
TheraCryf has announced a key manufacturing milestone for Ox-1, its lead orexin-1 blocker being developed as a potential treatment for addictive disorders, successfully scaling up production of the drug substance to 10.6kg with yields above target to support 28-day regulatory toxicology studies in two species. With maximum tolerated dose and dose range-finding work now underway, the company expects these toxicology studies to begin in the first half of 2026 and complete in the third quarter, positioning Ox-1 closer to clinical trial readiness and an associated regulatory submission, while engaging investors through a webinar to highlight recent progress and upcoming value inflection points in 2026.
The most recent analyst rating on (GB:TCF) stock is a Hold with a £0.20 price target. To see the full list of analyst forecasts on Evgen Pharma stock, see the GB:TCF Stock Forecast page.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and persistent cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate milestones provide some offset, but valuation signals are limited due to negative earnings and no dividend support.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical-stage drug development company focused on brain disorders, with a pipeline spanning addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its strategy is to generate preclinical and clinical proof-of-concept data and then partner its programmes with mid-sized to large pharmaceutical companies for late-stage trials and commercialisation. The company operates from Alderley Park, Cheshire, is quoted on AIM in London under the ticker TCF, and maintains collaborations with industry partners such as Stalicla SA and leading academic centres including the University of Manchester, King’s College London and the University of Michigan.
Average Trading Volume: 2,144,227
Technical Sentiment Signal: Sell
Current Market Cap: £4.3M
For an in-depth examination of TCF stock, go to TipRanks’ Overview page.